Agilent Technologies, Inc. · A
$1.6B
$1.7B
$1.7B
$1.6B
$1.7B
$1.8B
$1.8B
$1.7B
$1.7B
$1.7B
$1.7B
$1.6B
$1.6B
$1.7B
$1.7B
$1.7B
$1.7B
$1.9B
$1.8B
$1.8B
20-quarter listed-company comparison
Diagnostics & Research Stocks
Diagnostics & Research: Agilent Technologies, Inc. owns the largest revenue base; BillionToOne, Inc. has the fastest current growth.
01 · the industry itself · before any single company
How has Diagnostics & Research moved against S&P 500?
The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the most recent two of them this industry is 26% ahead of S&P 500. Earnings across its companies grew 7% on average over the last four reported quarters — close to flat. It has been ahead of S&P 500 on a rolling three-month view for 10 weeks running.
BREAKING OUT · ahead 10w~Price up, without the fundamentals confirming31 of 33 companies ahead of S&P 500 by 5% or more over three months2 are 20% or more behind over a year while earnings grew 20% or more
RS ↑10w · 26/33 >200d (+3) · 31/33 lead (+8) · EPS 19/33↑
Diagnostics & Research, equal-weighted, based at 200
S&P 500, same base, same start
trailing 12-month earnings per share rising
falling
Diagnostics & Research, equal-weighted, based at 200
S&P 500, same base, same start
trailing 12-month earnings per share rising
falling
Diagnostics & Research, equal-weighted, based at 200
S&P 500, same base, same start
trailing 12-month earnings per share rising
falling
Both lines start at 200 in the same week, so the distance between them is the whole story: the industry line is an equal-weighted index of its 33 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the industry taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.
02 · sector relative strength, before individual stocks
Is Diagnostics & Research outperforming S&P 500?
Diagnostics & Research has outperformed S&P 500 by 38.7% over the last 52 weeks. Over 13 weeks the gap is a lead of 33.7%. 17 of 29 covered companies currently beat the S&P 500 on Mansfield relative strength, so leadership inside the sector is selective. CareDx, Inc. is the strongest against the sector itself at +81.9%.
+33.7%Sector vs S&P 500 · 13 weeks
+38.7%Sector vs S&P 500 · 52 weeks
17/29Stocks leading S&P 500
8/29Stocks leading sector
Sector metric: — as of latest available · unclassified · direction unavailable.
The central tension: the companies with the most scale are not necessarily the companies creating the most change.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
Diagnostics & Research has outperformed S&P 500 by 38.7% over 52 weeks and 33.7% over 13 weeks. 17 of 29 covered companies beat the S&P 500 on Mansfield relative strength, while 8 of 29 beat the sector itself. Agilent Technologies, Inc. leads with revenue of $7,232 million, based on 12 of 30 comparable companies through Jun 2026.
Companies
30
complete canonical membership
Combined market value
$784.0B
Thermo Fisher Scientific Inc.
Revenue growing
11/12
positive TTM year-on-year growth
Beating S&P 500
17/29
positive Mansfield relative strength
Comparing 5 of 30
03 · research priority, made explicit
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
Medpace Holdings, Inc. has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 57.8% evidence confidence.
Twist Bioscience Corporation has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.
How this score is built, and what the marks mean
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Medpace Holdings, Inc.MEDP | 60.6/100Thin evidence · provisional58% evidence | TURNING | 21.1/35 Revenue — · PAT — · OPM change -0.3 pp 45% evidence | 21.3/25 ROCE 30.2% · OPM 20% 76% evidence | 10.5/20 P/E 31× · PEG — 15% evidence | 7.7/20 RS sector -13.3% · RS bench 0.3% · 1Y 32.4%3 of 12 weeks ahead 100% evidence |
| Exact sum: 21.1 + 21.3 + 10.5 + 7.7 = 60.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Agilent Technologies, Inc.A | 56.8/100Mixed-positive evidence85% evidence | BREAKING OUT | 22.5/35 Revenue 9.1% · PAT 21.3% · OPM change 3.7 pp 95% evidence | 16.1/25 ROCE 3.8% · OPM 21.7% 76% evidence | 14.4/20 P/E 23.2× · PEG 1.01 65% evidence | 3.8/20 RS sector -17.5% · RS bench -4.3% · 1Y 21.4%6 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 16.1 + 14.4 + 3.8 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Illumina, Inc.ILMN | 56.5/100Thin evidence · provisional58% evidence | LEADER | 18.1/35 Revenue — · PAT — · OPM change 3.4 pp 45% evidence | 14.3/25 ROCE 5.1% · OPM 19.2% 76% evidence | 10.3/20 P/E 32.9× · PEG — 15% evidence | 13.8/20 RS sector 18.4% · RS bench 36.7% · 1Y 114.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 14.3 + 10.3 + 13.8 = 56.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Adaptive Biotechnologies CorporationADPT | 55.5/100Thin evidence · provisional55% evidence | BREAKING OUT | 21.6/35 Revenue — · PAT — · OPM change 29.3 pp 45% evidence | 5.7/25 ROCE -3.3% · OPM -27.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 18.2/20 RS sector 19.2% · RS bench 37.1% · 1Y 101.2%9 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 5.7 + 10 + 18.2 = 55.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5NeoGenomics, Inc.NEO | 54.7/100Thin evidence · provisional58% evidence | BREAKING OUT | 21.0/35 Revenue — · PAT — · OPM change 6.8 pp 45% evidence | 6.0/25 ROCE -0.8% · OPM -9.8% 76% evidence | 9.0/20 P/E 134× · PEG — 15% evidence | 18.7/20 RS sector 22.1% · RS bench 39.9% · 1Y 180.9%10 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 6 + 9 + 18.7 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6IDEXX Laboratories, Inc.IDXX | 54.1/100Mixed-positive evidence81% evidence | TURNING | 22.8/35 Revenue 13.1% · PAT 22.4% · OPM change 0.1 pp 83% evidence | 20.1/25 ROCE 17.4% · OPM 31.8% 76% evidence | 10.1/20 P/E 41.4× · PEG 1.62 65% evidence | 1.1/20 RS sector -27.4% · RS bench -15.5% · 1Y -10.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.8 + 20.1 + 10.1 + 1.1 = 54.1 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -27.4% and the one-year return is -10.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 7Mettler-Toledo International Inc.MTD | 53.9/100Thin evidence · provisional58% evidence | TURNING | 17.4/35 Revenue — · PAT — · OPM change -0.8 pp 45% evidence | 18.4/25 ROCE 12.9% · OPM 23.9% 76% evidence | 10.6/20 P/E 28.8× · PEG — 15% evidence | 7.5/20 RS sector -15.6% · RS bench -2% · 1Y 14.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17.4 + 18.4 + 10.6 + 7.5 = 53.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Quest Diagnostics IncorporatedDGX | 52.5/100Thin evidence · provisional58% evidence | TURNING | 17.0/35 Revenue — · PAT — · OPM change 0.8 pp 45% evidence | 14.7/25 ROCE 3.2% · OPM 13.8% 76% evidence | 11.2/20 P/E 22.5× · PEG — 15% evidence | 9.6/20 RS sector -6.6% · RS bench 8.8% · 1Y 32.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 14.7 + 11.2 + 9.6 = 52.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Natera, Inc.NTRA | 51.3/100Mixed-positive evidence61% evidence | BREAKING OUT | 21.3/35 Revenue 36.6% · PAT — · OPM change 2.4 pp 62% evidence | 5.4/25 ROCE -5.5% · OPM -13.4% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.6/20 RS sector 1.4% · RS bench 17% · 1Y 81.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.3 + 5.4 + 10 + 14.6 = 51.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Charles River Laboratories International, Inc.CRL | 50.7/100Mixed-positive evidence64% evidence | BREAKING OUT | 18.0/35 Revenue 0.1% · PAT — · OPM change 4.4 pp 62% evidence | 11.7/25 ROCE 1.8% · OPM 12% 76% evidence | 8.8/20 P/E 427.2× · PEG — 15% evidence | 12.2/20 RS sector -0.8% · RS bench 14.6% · 1Y 57.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 11.7 + 8.8 + 12.2 = 50.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Labcorp Holdings Inc.LH | 50.7/100Thin evidence · provisional58% evidence | TURNING | 17.5/35 Revenue — · PAT — · OPM change 1.1 pp 45% evidence | 13.3/25 ROCE 2.8% · OPM 10.8% 76% evidence | 11.1/20 P/E 23.2× · PEG — 15% evidence | 8.8/20 RS sector -11.2% · RS bench 3.5% · 1Y 17.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 13.3 + 11.1 + 8.8 = 50.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Twist Bioscience CorporationTWST | 50.6/100Mixed-positive evidence61% evidence | BREAKING OUT | 16.7/35 Revenue 17.8% · PAT — · OPM change 3.4 pp 62% evidence | 4.7/25 ROCE -8.5% · OPM -41.4% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 19.2/20 RS sector 59.8% · RS bench 84.2% · 1Y 287.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 4.7 + 10 + 19.2 = 50.6 · Decision use: Price leads the evidence: RS versus the benchmark is 84.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 13IQVIA Holdings Inc.IQV | 50.0/100Thin evidence · provisional58% evidence | BREAKING OUT | 16.0/35 Revenue — · PAT — · OPM change -0.6 pp 45% evidence | 13.7/25 ROCE 2.4% · OPM 12.4% 76% evidence | 10.8/20 P/E 24× · PEG — 15% evidence | 9.5/20 RS sector -10.1% · RS bench 4% · 1Y 26.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 16 + 13.7 + 10.8 + 9.5 = 50 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Veracyte, Inc.VCYT | 49.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 21.2/35 Revenue — · PAT — · OPM change 13.8 pp 45% evidence | 11.0/25 ROCE 1.7% · OPM 16.3% 76% evidence | 9.5/20 P/E 41.7× · PEG — 15% evidence | 7.5/20 RS sector -9.6% · RS bench 4.2% · 1Y 69.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 11 + 9.5 + 7.5 = 49.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15CareDx, Inc.CDNA | 48.7/100Thin evidence · provisional52% evidence | BREAKING OUT | 15.5/35 Revenue — · PAT — · OPM change 16.8 pp 45% evidence | 4.7/25 ROCE -28.5% · OPM 1% 76% evidence | 11.5/20 P/E 13.8× · PEG — 15% evidence | 17.0/20 RS sector 81.9% · RS bench 108.8% · 1Y 293.4%12 of 12 weeks ahead 70% evidence |
| Exact sum: 15.5 + 4.7 + 11.5 + 17 = 48.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Guardant Health, Inc.GH | 48.4/100Thin evidence · provisional55% evidence | BREAKING OUT | 16.5/35 Revenue — · PAT — · OPM change 14.4 pp 45% evidence | 4.3/25 ROCE -9.7% · OPM -40.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 17.6/20 RS sector 25% · RS bench 43.3% · 1Y 194.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 4.3 + 10 + 17.6 = 48.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Sotera Health CompanySHC | 48.1/100Mixed-negative evidence64% evidence | BREAKING OUT | 19.3/35 Revenue 7.3% · PAT 100% · OPM change 4.7 pp 62% evidence | 14.3/25 ROCE 2.6% · OPM 27.1% 76% evidence | 9.9/20 P/E 35× · PEG — 15% evidence | 4.6/20 RS sector -14.7% · RS bench -1% · 1Y 29.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 14.3 + 9.9 + 4.6 = 48.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Thermo Fisher Scientific Inc.TMO | 46.3/100Thin evidence · provisional58% evidence | TURNING | 17.5/35 Revenue — · PAT — · OPM change 0.3 pp 45% evidence | 14.2/25 ROCE 2.2% · OPM 16.9% 76% evidence | 10.7/20 P/E 27.6× · PEG — 15% evidence | 3.9/20 RS sector -16.8% · RS bench -3.6% · 1Y 22.6%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 14.2 + 10.7 + 3.9 = 46.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Qiagen N.V.QGEN | 45.7/100Mixed-negative evidence71% evidence | TURNING | 15.7/35 Revenue 4.8% · PAT 100% · OPM change -6.8 pp 83% evidence | 12.9/25 ROCE 1.6% · OPM 17.1% 76% evidence | 11.4/20 P/E 20.9× · PEG — 15% evidence | 5.7/20 RS sector -27.4% · RS bench -15.6% · 1Y -16.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 12.9 + 11.4 + 5.7 = 45.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Danaher CorporationDHR | 44.5/100Thin evidence · provisional58% evidence | TURNING | 18.5/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 13.8/25 ROCE 1.4% · OPM 22.6% 76% evidence | 10.1/20 P/E 34.8× · PEG — 15% evidence | 2.1/20 RS sector -26% · RS bench -14.1% · 1Y -2.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18.5 + 13.8 + 10.1 + 2.1 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Castle Biosciences, Inc.CSTL | 43.2/100Thin evidence · provisional52% evidence | TURNING | 18.9/35 Revenue — · PAT — · OPM change 9.7 pp 45% evidence | 6.8/25 ROCE -0.6% · OPM -22% 76% evidence | 9.3/20 P/E 43× · PEG — 15% evidence | 8.2/20 RS sector -12.6% · RS bench 0.4% · 1Y 61.1%2 of 12 weeks ahead 70% evidence |
| Exact sum: 18.9 + 6.8 + 9.3 + 8.2 = 43.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Revvity, Inc.RVTY | 42.8/100Thin evidence · provisional58% evidence | BREAKING OUT | 15.2/35 Revenue — · PAT — · OPM change -1.9 pp 45% evidence | 11.5/25 ROCE 0.7% · OPM 10.7% 76% evidence | 9.4/20 P/E 42.6× · PEG — 15% evidence | 6.7/20 RS sector -11.4% · RS bench 2.7% · 1Y 28.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 15.2 + 11.5 + 9.4 + 6.7 = 42.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23OPKO Health, Inc.OPK | 42.8/100Thin evidence · provisional52% evidence | TURNING | 21.2/35 Revenue — · PAT — · OPM change 3.7 pp 45% evidence | 7.1/25 ROCE -0.4% · OPM -41.1% 76% evidence | 10.2/20 P/E 33.2× · PEG — 15% evidence | 4.3/20 RS sector -23.4% · RS bench -10.7% · 1Y 4.8%9 of 12 weeks ahead 70% evidence |
| Exact sum: 21.2 + 7.1 + 10.2 + 4.3 = 42.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24GRAIL, Inc.GRAL | 38.8/100Mixed-negative evidence61% evidence | BREAKING OUT | 21.2/35 Revenue 19.9% · PAT — · OPM change 149.6 pp 62% evidence | 4.7/25 ROCE -4.9% · OPM -332.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.9/20 RS sector -16.4% · RS bench -4.6% · 1Y 121.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 4.7 + 10 + 2.9 = 38.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25ICON Public Limited CompanyICLR | 38.7/100Thin evidence · provisional58% evidence | BREAKING OUT | 13.8/35 Revenue — · PAT — · OPM change -2.8 pp 45% evidence | 10.5/25 ROCE 1% · OPM 8.5% 76% evidence | 8.9/20 P/E 310.2× · PEG — 15% evidence | 5.5/20 RS sector -20.7% · RS bench -8.3% · 1Y -1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 10.5 + 8.9 + 5.5 = 38.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Waters CorporationWAT | 38.3/100Thin evidence · provisional58% evidence | BREAKING OUT | 12.0/35 Revenue — · PAT — · OPM change -28.1 pp 45% evidence | 9.6/25 ROCE -0.4% · OPM -3.7% 76% evidence | 9.8/20 P/E 38.7× · PEG — 15% evidence | 6.9/20 RS sector -11.4% · RS bench 2.6% · 1Y 40.9%10 of 12 weeks ahead 100% evidence |
| Exact sum: 12 + 9.6 + 9.8 + 6.9 = 38.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27RadNet, Inc.RDNT | 37.9/100Mixed-negative evidence64% evidence | TURNING | 17.9/35 Revenue 14.8% · PAT 100% · OPM change 0.9 pp 62% evidence | 8.3/25 ROCE -0.8% · OPM -4.2% 76% evidence | 8.6/20 P/E 1746× · PEG — 15% evidence | 3.1/20 RS sector -21.2% · RS bench -8.5% · 1Y 29.8%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 8.3 + 8.6 + 3.1 = 37.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Personalis, Inc.PSNL | 37.0/100Thin evidence · provisional55% evidence | BREAKING OUT | 7.3/35 Revenue -27.6% · PAT — · OPM change -122 pp 62% evidence | 3.7/25 ROCE -12.1% · OPM -207.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 16.0/20 RS sector 24.8% · RS bench 42.5% · 1Y 199.8%11 of 12 weeks ahead 70% evidence |
| Exact sum: 7.3 + 3.7 + 10 + 16 = 37 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29GeneDx Holdings Corp.WGS | 30.9/100Adverse evidence64% evidence | TURNING | 12.6/35 Revenue 33.8% · PAT — · OPM change -51 pp 62% evidence | 4.1/25 ROCE -14.4% · OPM -56.2% 76% evidence | 8.5/20 P/E 2693.5× · PEG — 15% evidence | 5.7/20 RS sector -43.7% · RS bench -34.9% · 1Y -32.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 12.6 + 4.1 + 8.5 + 5.7 = 30.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30BillionToOne, Inc.BLLN | 58.3/100Thin evidence · provisional44% evidence | BREAKING OUT | 26.0/35 Revenue 99.4% · PAT — · OPM change 20.4 pp 62% evidence | 13.1/25 ROCE 3.9% · OPM 16.5% 76% evidence | 9.2/20 P/E 60.9× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —11 of 12 weeks ahead 0% evidence |
| Exact sum: 26 + 13.1 + 9.2 + 10 = 58.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Showing 10 of 30 companies
04 · what price has already done
Market action
CareDx, Inc. has the strongest one-year price move in Diagnostics & Research at +293.4%. It also leads on Mansfield relative strength against the S&P 500 at +108.8%. 17 of 29 covered companies are above zero on that measure. Every line covers 314 weekly closes through 2026-08-04.
Price and relative strength
Every company, the sector's own index and S&P 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
How far ahead of or behind S&P 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS S&P 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
The same measure taken against Diagnostics & Research itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
05 · compare level, then change
Revenue Scale & Growth Durability
Agilent Technologies, Inc. has the highest Revenue among the 30 Diagnostics & Research companies compared here, at $7,232 million. IDEXX Laboratories, Inc. is next at $4,446 million. BillionToOne, Inc. has the highest Revenue growth at 99.4%, so level and change sit with different companies. 12 of 30 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Agilent Technologies, Inc. is the scale leader at $7,232 million, 62.7% ahead of IDEXX Laboratories, Inc.. BillionToOne, Inc.'s growth is 99.4% from a $355 million base, with 9 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderAgilent Technologies, Inc. · $7,232 million
Gap62.7% versus #2 · IDEXX Laboratories, Inc.
Persistence7/8 recent comparable periods
Coverage12/30 companies · 548 observations
Investor read: Agilent Technologies, Inc. is the scale benchmark; BillionToOne, Inc. is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: Agilent Technologies, Inc.'s growth falls below BillionToOne, Inc.'s for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
Revenue growthfastest growers
Revenue · company comparison
12/30 level · 12/30 change
On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Thermo Fisher Scientific Inc. TMO | $11.0B | 6.2% | Jun 2026 |
| Danaher Corporation DHR | $6.0B | 3.7% | Jun 2026 |
| IQVIA Holdings Inc. IQV | $4.2B | 8.4% | Jun 2026 |
| Labcorp Holdings Inc. LH | $3.5B | 5.8% | Jun 2026 |
| Quest Diagnostics Incorporated DGX | $2.9B | 9.2% | Jun 2026 |
| ICON Public Limited Company ICLR | $2.0B | 0.9% | Jun 2026 |
| Agilent Technologies, Inc. A | $1.8B | 10% | Jun 2026 |
| Waters Corporation WAT | $1.3B | 64% | Jun 2026 |
| IDEXX Laboratories, Inc. IDXX | $1.1B | 14% | Mar 2026 |
| Illumina, Inc. ILMN | $1.1B | 4.8% | Jun 2026 |
| Charles River Laboratories International, Inc. CRL | $996M | 1.2% | Mar 2026 |
| Mettler-Toledo International Inc. MTD | $947M | 7.1% | Jun 2026 |
| Revvity, Inc. RVTY | $711M | -1.3% | Jun 2026 |
| Medpace Holdings, Inc. MEDP | $707M | 26% | Jun 2026 |
| Natera, Inc. NTRA | $697M | 39% | Mar 2026 |
| RadNet, Inc. RDNT | $576M | 22% | Mar 2026 |
| Qiagen N.V. QGEN | $492M | 1.9% | Mar 2026 |
| Guardant Health, Inc. GH | $302M | 49% | Jun 2026 |
| Sotera Health Company SHC | $280M | 9.8% | Mar 2026 |
| NeoGenomics, Inc. NEO | $187M | 11% | Jun 2026 |
| Veracyte, Inc. VCYT | $139M | 22% | Jun 2026 |
| OPKO Health, Inc. OPK | $124M | -17% | Jun 2026 |
| CareDx, Inc. CDNA | $118M | 39% | Jun 2026 |
| Twist Bioscience Corporation TWST | $111M | 19% | Mar 2026 |
| BillionToOne, Inc. BLLN | $108M | 83% | Mar 2026 |
| GeneDx Holdings Corp. WGS | $102M | 17% | Mar 2026 |
| Castle Biosciences, Inc. CSTL | $84M | -4.6% | Jun 2026 |
| Adaptive Biotechnologies Corporation ADPT | $71M | 37% | Jun 2026 |
| GRAIL, Inc. GRAL | $41M | 28% | Mar 2026 |
| Personalis, Inc. PSNL | $15M | -29% | Mar 2026 |
Full 20-quarter history · every available company
Revenue · reported quarter history
Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Danaher Corporation · DHR
$7.2B
$7.2B
—
$7.7B
$7.8B
$7.1B
$5.9B
$5.9B
$5.6B
$6.4B
$5.8B
$5.7B
$5.8B
$6.5B
$5.7B
$5.9B
$6.1B
$6.8B
$6.0B
—
Guardant Health, Inc. · GH
$95M
$108M
$96M
$109M
$117M
$127M
$129M
$137M
$143M
$155M
$168M
$177M
$191M
$202M
$203M
$232M
$265M
$281M
$302M
—
IDEXX Laboratories, Inc. · IDXX
$810M
$801M
$837M
$861M
$842M
$829M
$900M
$944M
$916M
$902M
$964M
$1.0B
$976M
$954M
$998M
$1.1B
$1.1B
$1.1B
$1.1B
—
Illumina, Inc. · ILMN
$1.1B
$1.1B
$1.2B
$1.2B
$1.2B
$1.1B
$1.1B
$1.1B
$1.2B
$1.1B
$1.1B
$1.1B
$1.1B
$1.1B
$1.0B
$1.1B
$1.1B
$1.2B
$1.1B
—
IQVIA Holdings Inc. · IQV
$3.4B
$3.6B
$3.6B
$3.5B
$3.6B
$3.7B
$3.7B
$3.7B
$3.7B
$3.9B
$3.7B
$3.8B
$3.9B
$4.0B
$3.8B
$4.0B
$4.1B
$4.4B
$4.2B
—
Labcorp Holdings Inc. · LH
$4.1B
$4.1B
$3.9B
$2.9B
$2.9B
$2.9B
$3.0B
$3.0B
$3.1B
$3.0B
$3.2B
$3.2B
$3.3B
$3.3B
$3.3B
$3.5B
$3.6B
$3.5B
$3.5B
—
Mettler-Toledo International Inc. · MTD
$952M
$1.0B
$898M
$978M
$986M
$1.1B
$929M
$982M
$942M
$935M
$926M
$947M
$955M
$1.0B
$884M
$983M
$1.0B
$1.1B
$947M
—
Natera, Inc. · NTRA
$158M
$173M
$194M
$198M
$211M
$217M
$242M
$261M
$268M
$311M
$368M
$413M
$440M
$476M
$502M
$547M
$592M
$665M
$697M
—
Quest Diagnostics Incorporated · DGX
$2.8B
$2.7B
$2.6B
$2.5B
$2.5B
$2.3B
$2.3B
$2.3B
$2.3B
$2.3B
$2.4B
$2.4B
$2.5B
$2.6B
$2.7B
$2.8B
$2.8B
$2.8B
$2.9B
—
Thermo Fisher Scientific Inc. · TMO
$9.3B
$9.3B
—
$11.8B
$11.0B
$10.7B
—
$10.7B
$10.7B
$10.9B
$10.3B
$10.5B
$10.6B
$11.4B
$10.4B
$10.9B
$11.1B
$12.2B
$11.0B
—
Waters Corporation · WAT
$682M
$659M
—
$691M
$714M
$709M
—
$685M
$741M
$819M
$637M
$709M
$740M
$873M
$662M
$771M
$800M
$932M
—
$1.3B
Revenue growth · reported quarter history
Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Agilent Technologies, Inc. · A
—
—
—
—
8.3%
11%
4.9%
6.9%
-2.7%
-8.7%
-5.6%
-8.4%
-5.6%
0.8%
1.4%
6.0%
10%
9.4%
7.0%
10%
Danaher Corporation · DHR
—
—
—
—
7.4%
-1.3%
—
-23%
-27%
-10%
-2.6%
-2.9%
3.1%
2.1%
-1.0%
3.4%
4.4%
4.6%
3.7%
—
Guardant Health, Inc. · GH
—
—
—
18%
23%
18%
34%
26%
22%
22%
30%
29%
34%
30%
21%
31%
39%
39%
49%
—
IDEXX Laboratories, Inc. · IDXX
—
—
—
4.2%
4.0%
3.5%
7.5%
9.6%
8.8%
8.8%
7.1%
6.4%
6.6%
5.8%
3.5%
10%
13%
14%
14%
—
Illumina, Inc. · ILMN
—
—
—
—
3.2%
0.6%
-9.7%
-11%
1.2%
0.4%
-0.7%
2.3%
-8.2%
-1.3%
-3.3%
-4.8%
0.4%
5.0%
4.8%
—
IQVIA Holdings Inc. · IQV
—
—
—
3.0%
5.0%
2.8%
2.4%
5.3%
4.9%
3.5%
2.3%
2.3%
4.3%
2.3%
2.5%
5.3%
5.2%
10%
8.4%
—
Labcorp Holdings Inc. · LH
—
—
—
-24%
-29%
-28%
-22%
3.8%
6.6%
3.5%
4.6%
6.2%
7.4%
9.8%
5.3%
9.5%
8.6%
5.6%
5.8%
—
Mettler-Toledo International Inc. · MTD
—
—
—
5.8%
3.6%
2.0%
3.5%
0.4%
-4.5%
-12%
-0.3%
-3.6%
1.4%
12%
-4.5%
3.8%
7.9%
8.1%
7.1%
—
Natera, Inc. · NTRA
—
—
—
39%
34%
25%
25%
32%
27%
43%
52%
58%
64%
53%
36%
32%
35%
40%
39%
—
Quest Diagnostics Incorporated · DGX
—
—
—
-3.8%
-10%
-15%
-11%
-4.7%
-7.7%
-1.9%
1.5%
2.5%
8.4%
15%
12%
15%
13%
7.1%
9.2%
—
Thermo Fisher Scientific Inc. · TMO
—
—
—
—
18%
14%
—
-9.4%
-2.6%
2.0%
—
-1.6%
-0.8%
4.7%
0.2%
3.0%
4.9%
7.2%
6.2%
—
Waters Corporation · WAT
—
—
—
—
4.7%
7.6%
—
-0.9%
3.8%
16%
—
3.5%
-0.1%
6.6%
3.9%
8.7%
8.1%
6.8%
—
64%
06 · compare level, then change
Operating Economics & Margin Trend
IDEXX Laboratories, Inc. has the highest OPM among the 30 Diagnostics & Research companies compared here, at 31.8%. Sotera Health Company is next at 27.1%. GRAIL, Inc. has the highest Margin change at +149.6 percentage points, so level and change sit with different companies. 30 of 30 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: IDEXX Laboratories, Inc. leads opm at 31.8%; GRAIL, Inc. leads margin change at +149.6 percentage points.
LeaderIDEXX Laboratories, Inc. · 31.8%
Gap17.3% versus #2 · Sotera Health Company
Persistence7/8 recent comparable periods
Coverage30/30 companies · 545 observations
Investor read: IDEXX Laboratories, Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
Margin changefastest expanders
Operating margin · company comparison
30/30 level · 30/30 change
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| IDEXX Laboratories, Inc. IDXX | 32% | +0.1 pp | Mar 2026 |
| Sotera Health Company SHC | 27% | +4.7 pp | Mar 2026 |
| Mettler-Toledo International Inc. MTD | 24% | −0.8 pp | Jun 2026 |
| Danaher Corporation DHR | 23% | +0.4 pp | Jun 2026 |
| Agilent Technologies, Inc. A | 22% | +3.7 pp | Jun 2026 |
| Medpace Holdings, Inc. MEDP | 20% | −0.3 pp | Jun 2026 |
| Illumina, Inc. ILMN | 19% | +3.4 pp | Jun 2026 |
| Qiagen N.V. QGEN | 17% | −6.8 pp | Mar 2026 |
| Thermo Fisher Scientific Inc. TMO | 17% | +0.3 pp | Jun 2026 |
| BillionToOne, Inc. BLLN | 17% | +20.4 pp | Mar 2026 |
| Veracyte, Inc. VCYT | 16% | +13.8 pp | Jun 2026 |
| Quest Diagnostics Incorporated DGX | 14% | +0.8 pp | Jun 2026 |
| IQVIA Holdings Inc. IQV | 12% | −0.6 pp | Jun 2026 |
| Charles River Laboratories International, Inc. CRL | 12% | +4.4 pp | Mar 2026 |
| Labcorp Holdings Inc. LH | 11% | +1.1 pp | Jun 2026 |
| Revvity, Inc. RVTY | 11% | −1.9 pp | Jun 2026 |
| ICON Public Limited Company ICLR | 8.5% | −2.8 pp | Jun 2026 |
| CareDx, Inc. CDNA | 1.0% | +16.8 pp | Jun 2026 |
| Waters Corporation WAT | -3.7% | −28.1 pp | Jun 2026 |
| RadNet, Inc. RDNT | -4.2% | +0.9 pp | Mar 2026 |
| NeoGenomics, Inc. NEO | -9.8% | +6.8 pp | Jun 2026 |
| Natera, Inc. NTRA | -13% | +2.4 pp | Mar 2026 |
| Castle Biosciences, Inc. CSTL | -22% | +9.7 pp | Jun 2026 |
| Adaptive Biotechnologies Corporation ADPT | -27% | +29.3 pp | Jun 2026 |
| Guardant Health, Inc. GH | -40% | +14.4 pp | Jun 2026 |
| OPKO Health, Inc. OPK | -41% | +3.7 pp | Jun 2026 |
| Twist Bioscience Corporation TWST | -41% | +3.4 pp | Mar 2026 |
| GeneDx Holdings Corp. WGS | -56% | −51.0 pp | Mar 2026 |
| Personalis, Inc. PSNL | -208% | −122.0 pp | Mar 2026 |
| GRAIL, Inc. GRAL | -333% | +149.6 pp | Mar 2026 |
Full 20-quarter history · every available company
OPM · reported quarter history
Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Agilent Technologies, Inc. · A
21%
24%
23%
22%
24%
26%
24%
22%
8.0%
24%
23%
23%
21%
24%
22%
18%
21%
24%
20%
22%
Danaher Corporation · DHR
28%
18%
—
28%
28%
28%
26%
20%
21%
21%
23%
20%
17%
22%
22%
13%
19%
22%
23%
—
Guardant Health, Inc. · GH
-113%
-91%
-128%
-119%
-123%
-115%
-104%
-87%
-79%
-127%
-59%
-57%
-61%
-62%
-55%
-46%
-37%
-43%
-40%
—
IDEXX Laboratories, Inc. · IDXX
28%
25%
30%
21%
29%
27%
31%
31%
30%
27%
31%
26%
31%
27%
32%
34%
32%
29%
32%
—
Illumina, Inc. · ILMN
17%
-49%
3.4%
15%
-50%
-328%
-12%
-5.9%
-7.5%
-67%
-10%
-147%
69%
16%
16%
20%
21%
17%
19%
—
IQVIA Holdings Inc. · IQV
8.9%
13%
14%
13%
13%
10%
13%
14%
13%
13%
14%
14%
14%
16%
13%
13%
14%
14%
12%
—
Labcorp Holdings Inc. · LH
19%
18%
18%
15%
13%
1.0%
11%
8.8%
8.3%
-4.0%
10%
9.2%
7.7%
6.5%
9.7%
11%
11%
7.6%
11%
—
Mettler-Toledo International Inc. · MTD
27%
29%
25%
28%
30%
32%
26%
29%
29%
27%
26%
28%
29%
32%
25%
27%
28%
30%
24%
—
Natera, Inc. · NTRA
-95%
-81%
-71%
-72%
-57%
-65%
-57%
-43%
-41%
-27%
-20%
-11%
-8.9%
-14%
-16%
-20%
-17%
-3.4%
-13%
—
Quest Diagnostics Incorporated · DGX
24%
20%
20%
16%
16%
5.8%
13%
15%
15%
12%
13%
15%
13%
14%
13%
16%
14%
14%
14%
—
Thermo Fisher Scientific Inc. · TMO
23%
24%
—
24%
18%
16%
—
15%
15%
17%
16%
17%
17%
18%
17%
17%
18%
19%
17%
—
Waters Corporation · WAT
29%
29%
—
28%
28%
27%
—
25%
27%
32%
21%
27%
29%
34%
23%
24%
24%
29%
—
-3.7%
Margin change · reported quarter history
Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Agilent Technologies, Inc. · A
—
—
—
—
+2.7 pp
+1.7 pp
+1.8 pp
−0.1 pp
−15.9 pp
−1.3 pp
−1.1 pp
+0.8 pp
+13.1 pp
−0.2 pp
−0.8 pp
−5.1 pp
−0.4 pp
−0.2 pp
−2.8 pp
+3.7 pp
Danaher Corporation · DHR
—
—
—
—
+0.6 pp
+9.9 pp
—
−8.6 pp
−7.3 pp
−7.1 pp
−2.9 pp
+0.6 pp
−4.6 pp
+0.9 pp
−0.4 pp
−7.5 pp
+2.6 pp
+0.2 pp
+0.4 pp
—
Guardant Health, Inc. · GH
—
—
—
−13.4 pp
−10.0 pp
−24.4 pp
+24.1 pp
+32.2 pp
+43.8 pp
−12.2 pp
+45.0 pp
+30.4 pp
+18.1 pp
+65.0 pp
+4.6 pp
+10.9 pp
+24.0 pp
+19.4 pp
+14.4 pp
—
IDEXX Laboratories, Inc. · IDXX
—
—
—
−10.6 pp
+1.2 pp
+2.4 pp
+1.4 pp
+10.6 pp
+1.0 pp
−0.1 pp
−0.1 pp
−5.1 pp
+1.1 pp
+0.2 pp
+0.7 pp
+7.3 pp
+0.9 pp
+1.5 pp
+0.1 pp
—
Illumina, Inc. · ILMN
—
—
—
—
−66.4 pp
−278.8 pp
−15.1 pp
−20.9 pp
+42.3 pp
+260.6 pp
+1.4 pp
−141.3 pp
+76.1 pp
+83.3 pp
+26.1 pp
+167.4 pp
−47.7 pp
+1.4 pp
+3.4 pp
—
IQVIA Holdings Inc. · IQV
—
—
—
+4.5 pp
+4.4 pp
−2.6 pp
−1.0 pp
+1.3 pp
−0.4 pp
+2.9 pp
+0.6 pp
−0.5 pp
+1.2 pp
+2.8 pp
−0.5 pp
−1.0 pp
−0.6 pp
−1.4 pp
−0.6 pp
—
Labcorp Holdings Inc. · LH
—
—
—
−3.6 pp
−5.9 pp
−17.0 pp
−6.7 pp
−5.9 pp
−4.7 pp
−5.0 pp
−0.8 pp
+0.4 pp
−0.6 pp
+10.5 pp
−0.4 pp
+2.0 pp
+3.4 pp
+1.1 pp
+1.1 pp
—
Mettler-Toledo International Inc. · MTD
—
—
—
+1.4 pp
+2.3 pp
+3.3 pp
+1.4 pp
+1.3 pp
−0.7 pp
−5.4 pp
−0.5 pp
−1.1 pp
+0.3 pp
+4.9 pp
−1.2 pp
−0.7 pp
−1.2 pp
−1.7 pp
−0.8 pp
—
Natera, Inc. · NTRA
—
—
—
+9.0 pp
+38.5 pp
+15.4 pp
+13.4 pp
+29.2 pp
+15.1 pp
+38.1 pp
+37.0 pp
+32.4 pp
+32.5 pp
+13.6 pp
+4.4 pp
−9.6 pp
−7.6 pp
+10.2 pp
+2.4 pp
—
Quest Diagnostics Incorporated · DGX
—
—
—
−5.1 pp
−7.7 pp
−13.7 pp
−6.5 pp
−0.9 pp
−0.9 pp
+5.9 pp
−0.4 pp
−0.1 pp
−1.6 pp
+2.1 pp
+0.3 pp
+1.1 pp
+0.4 pp
0.0 pp
+0.8 pp
—
Thermo Fisher Scientific Inc. · TMO
—
—
—
—
−5.1 pp
−8.4 pp
—
−9.3 pp
−3.4 pp
+1.0 pp
—
+2.7 pp
+2.5 pp
+0.7 pp
+0.5 pp
−0.4 pp
+0.2 pp
+0.8 pp
+0.3 pp
—
Waters Corporation · WAT
—
—
—
—
−0.9 pp
−2.0 pp
—
−2.9 pp
−0.9 pp
+5.1 pp
—
+1.3 pp
+1.5 pp
+1.3 pp
+2.0 pp
−2.3 pp
−4.5 pp
−4.5 pp
—
−28.1 pp
07 · compare level, then change
Profit Scale & Acceleration
Agilent Technologies, Inc. has the highest Net profit among the 30 Diagnostics & Research companies compared here, at $1,414 million. IDEXX Laboratories, Inc. is next at $1,095 million. Qiagen N.V. has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.
What the numbers say: Agilent Technologies, Inc. leads with $1,414 million of TTM profit, 29.1% above IDEXX Laboratories, Inc.. Qiagen N.V. shows ≥100% on the scoring scale (327.7% uncapped) growth from a $402 million profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.
LeaderAgilent Technologies, Inc. · $1,414 million
Gap29.1% versus #2 · IDEXX Laboratories, Inc.
Persistence4/8 recent comparable periods
Coverage12/30 companies · 548 observations
Investor read: Agilent Technologies, Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
Profit growthfastest growers
Net profit · company comparison
12/30 level · 3/30 change
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Thermo Fisher Scientific Inc. TMO | $1.7B | 9.1% | Jun 2026 |
| Danaher Corporation DHR | $1.0B | 7.9% | Jun 2026 |
| Agilent Technologies, Inc. A | $339M | 58% | Jun 2026 |
| IDEXX Laboratories, Inc. IDXX | $278M | 14% | Mar 2026 |
| Labcorp Holdings Inc. LH | $278M | 31% | Jun 2026 |
| IQVIA Holdings Inc. IQV | $269M | 2.7% | Jun 2026 |
| Quest Diagnostics Incorporated DGX | $264M | 12% | Jun 2026 |
| Mettler-Toledo International Inc. MTD | $169M | 3.1% | Jun 2026 |
| Illumina, Inc. ILMN | $134M | 2.3% | Jun 2026 |
| Medpace Holdings, Inc. MEDP | $124M | 7.8% | Jun 2026 |
| ICON Public Limited Company ICLR | $105M | -35% | Jun 2026 |
| Qiagen N.V. QGEN | $68M | -25% | Mar 2026 |
| Revvity, Inc. RVTY | $41M | -25% | Jun 2026 |
| Veracyte, Inc. VCYT | $29M | 314% | Jun 2026 |
| Sotera Health Company SHC | $27M | 192% | Mar 2026 |
| BillionToOne, Inc. BLLN | $19M | — | Mar 2026 |
| CareDx, Inc. CDNA | $3M | -105% | Jun 2026 |
| Charles River Laboratories International, Inc. CRL | $-15M | -158% | Mar 2026 |
| Castle Biosciences, Inc. CSTL | $-15M | -120% | Jun 2026 |
| NeoGenomics, Inc. NEO | $-17M | -146% | Jun 2026 |
| Adaptive Biotechnologies Corporation ADPT | $-20M | — | Jun 2026 |
| RadNet, Inc. RDNT | $-25M | -29% | Mar 2026 |
| Personalis, Inc. PSNL | $-30M | — | Mar 2026 |
| Twist Bioscience Corporation TWST | $-44M | — | Mar 2026 |
| OPKO Health, Inc. OPK | $-55M | -321% | Jun 2026 |
| GeneDx Holdings Corp. WGS | $-63M | -460% | Mar 2026 |
| Waters Corporation WAT | $-72M | -149% | Jun 2026 |
| Natera, Inc. NTRA | $-85M | — | Mar 2026 |
| GRAIL, Inc. GRAL | $-93M | — | Mar 2026 |
| Guardant Health, Inc. GH | $-112M | — | Jun 2026 |
Full 20-quarter history · every available company
Net profit · reported quarter history
Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Agilent Technologies, Inc. · A
$264M
$442M
$283M
$274M
$329M
$368M
$352M
$302M
$111M
$475M
$348M
$308M
$282M
$351M
$318M
$215M
$336M
$434M
$305M
$339M
Danaher Corporation · DHR
$1.7B
$1.2B
—
$1.7B
$1.7B
$2.0B
$1.2B
$920M
$940M
$1.1B
$1.1B
$907M
$818M
$1.1B
$954M
$555M
$908M
$1.2B
$1.0B
—
Guardant Health, Inc. · GH
$-108M
$-72M
$-123M
$-229M
$-162M
$-140M
$-134M
$-73M
$-86M
$-187M
$-115M
$-103M
$-108M
$-111M
$-95M
$-100M
$-93M
$-128M
$-112M
—
IDEXX Laboratories, Inc. · IDXX
$175M
$163M
$194M
$132M
$181M
$172M
$214M
$224M
$212M
$195M
$236M
$203M
$233M
$216M
$243M
$294M
$275M
$248M
$278M
—
Illumina, Inc. · ILMN
$185M
$317M
$112M
$86M
$-535M
$-3.8B
$-139M
$3M
$-234M
$-754M
$-126M
$-2.0B
$705M
$187M
$131M
$235M
$150M
$334M
$134M
—
IQVIA Holdings Inc. · IQV
$261M
$317M
$329M
$257M
$290M
$227M
$291M
$294M
$298M
$475M
$291M
$361M
$284M
$432M
$262M
$267M
$332M
$478M
$269M
—
Labcorp Holdings Inc. · LH
$588M
$554M
$492M
$268M
$277M
$37M
$208M
$155M
$184M
$-167M
$228M
$206M
$170M
$144M
$213M
$238M
$262M
$165M
$278M
—
Mettler-Toledo International Inc. · MTD
$204M
$231M
$174M
$212M
$221M
$266M
$188M
$214M
$202M
$185M
$178M
$222M
$212M
$252M
$164M
$202M
$217M
$286M
$169M
—
Natera, Inc. · NTRA
$-151M
$-141M
$-139M
$-145M
$-121M
$-143M
$-137M
$-111M
$-109M
$-78M
$-68M
$-37M
$-32M
$-54M
$-67M
$-101M
$-88M
$47M
$-85M
—
Quest Diagnostics Incorporated · DGX
$527M
$413M
$373M
$250M
$276M
$116M
$217M
$249M
$237M
$205M
$208M
$240M
$237M
$236M
$235M
$296M
$259M
$256M
$264M
—
Thermo Fisher Scientific Inc. · TMO
$1.8B
$1.9B
—
$2.2B
$1.7B
$1.6B
—
$1.3B
$1.4B
$1.6B
$1.3B
$1.6B
$1.6B
$1.8B
$1.5B
$1.6B
$1.6B
$2.0B
$1.7B
—
Waters Corporation · WAT
$167M
$161M
—
$160M
$165M
$156M
—
$141M
$151M
$216M
$102M
$143M
$162M
$231M
$121M
$147M
$149M
$225M
—
$-72M
Profit growth · reported quarter history
Showing the 12 largest of 23 companies with a series here. The remaining 11 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Agilent Technologies, Inc. · A
—
—
—
—
25%
-17%
24%
10%
-66%
29%
-1.1%
2.0%
154%
-26%
-8.6%
-30%
19%
24%
-4.1%
58%
Danaher Corporation · DHR
—
—
—
—
-1.1%
74%
—
-47%
-44%
-44%
-12%
-1.4%
-13%
2.3%
-12%
-39%
11%
7.9%
7.9%
—
IDEXX Laboratories, Inc. · IDXX
—
—
—
-35%
3.4%
5.5%
10%
70%
17%
13%
10%
-9.4%
9.9%
11%
3.0%
45%
18%
15%
14%
—
Illumina, Inc. · ILMN
—
—
—
—
-389%
-1,304%
-224%
-97%
—
—
—
—
—
—
—
—
-79%
79%
2.3%
—
IQVIA Holdings Inc. · IQV
—
—
—
48%
11%
-28%
-12%
14%
2.8%
109%
0.0%
23%
-4.7%
-9.1%
-10.0%
-26%
17%
11%
2.7%
—
Labcorp Holdings Inc. · LH
—
—
—
-43%
-53%
-93%
-58%
-42%
-34%
-551%
9.6%
33%
-7.6%
—
-6.6%
16%
54%
15%
31%
—
Medpace Holdings, Inc. · MEDP
—
—
—
23%
35%
38%
20%
24%
7.6%
13%
41%
44%
35%
50%
12%
2.3%
16%
15%
7.8%
—
Mettler-Toledo International Inc. · MTD
—
—
—
15%
8.3%
15%
8.1%
0.9%
-8.6%
-30%
-5.3%
3.7%
5.0%
36%
-7.9%
-9.0%
2.4%
13%
3.1%
—
Quest Diagnostics Incorporated · DGX
—
—
—
-62%
-48%
-72%
-42%
-0.4%
-14%
77%
-4.2%
-3.6%
0.0%
15%
13%
23%
9.3%
8.5%
12%
—
Revvity, Inc. · RVTY
—
—
—
—
-34%
-35%
-47%
-86%
-64%
-54%
-70%
192%
58%
175%
45%
-25%
-49%
9.1%
—
-25%
Thermo Fisher Scientific Inc. · TMO
—
—
—
—
-6.1%
-18%
—
-41%
-20%
2.4%
—
24%
19%
11%
17%
-1.2%
-1.5%
12%
9.1%
—
Waters Corporation · WAT
—
—
—
—
-1.2%
-3.1%
—
-12%
-8.5%
38%
—
1.4%
7.3%
6.9%
19%
2.8%
-8.0%
-2.6%
—
-149%
08 · compare level, then change
Return On Capital Employed
Medpace Holdings, Inc. has the highest ROCE among the 30 Diagnostics & Research companies compared here, at 30.2%. IDEXX Laboratories, Inc. is next at 17.4%. The same company also holds the highest ROCE change, at +10.4 percentage points. 30 of 30 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Medpace Holdings, Inc. leads ROCE at 30.2%, 12.8 percentage points above IDEXX Laboratories, Inc.. Medpace Holdings, Inc. has the strongest latest improvement at +10.4 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderMedpace Holdings, Inc. · 30.2%
Gap73.6% versus #2 · IDEXX Laboratories, Inc.
Persistence6/8 recent comparable periods
Coverage30/30 companies · 556 observations
Investor read: Medpace Holdings, Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
ROCE changefastest improvers
Return on capital · company comparison
30/30 level · 30/30 change
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Medpace Holdings, Inc. MEDP | 30% | +10.4 pp | Jun 2026 |
| IDEXX Laboratories, Inc. IDXX | 17% | +3.3 pp | Mar 2026 |
| Mettler-Toledo International Inc. MTD | 13% | +0.4 pp | Jun 2026 |
| Illumina, Inc. ILMN | 5.1% | +0.1 pp | Jun 2026 |
| BillionToOne, Inc. BLLN | 3.9% | +5.6 pp | Mar 2026 |
| Agilent Technologies, Inc. A | 3.8% | +0.6 pp | Jun 2026 |
| Quest Diagnostics Incorporated DGX | 3.2% | −0.2 pp | Jun 2026 |
| Labcorp Holdings Inc. LH | 2.8% | 0.0 pp | Jun 2026 |
| Sotera Health Company SHC | 2.6% | +0.6 pp | Mar 2026 |
| IQVIA Holdings Inc. IQV | 2.4% | −0.1 pp | Jun 2026 |
| Thermo Fisher Scientific Inc. TMO | 2.2% | +0.1 pp | Jun 2026 |
| Charles River Laboratories International, Inc. CRL | 1.8% | +0.7 pp | Mar 2026 |
| Veracyte, Inc. VCYT | 1.7% | +2.1 pp | Jun 2026 |
| Qiagen N.V. QGEN | 1.6% | −0.8 pp | Mar 2026 |
| Danaher Corporation DHR | 1.4% | +0.4 pp | Jun 2026 |
| ICON Public Limited Company ICLR | 1.0% | −0.6 pp | Jun 2026 |
| Revvity, Inc. RVTY | 0.7% | −0.1 pp | Jun 2026 |
| Waters Corporation WAT | -0.4% | −5.5 pp | Jun 2026 |
| OPKO Health, Inc. OPK | -0.4% | +3.0 pp | Jun 2026 |
| Castle Biosciences, Inc. CSTL | -0.6% | +0.3 pp | Jun 2026 |
| RadNet, Inc. RDNT | -0.8% | +0.1 pp | Mar 2026 |
| NeoGenomics, Inc. NEO | -0.8% | +2.8 pp | Jun 2026 |
| Adaptive Biotechnologies Corporation ADPT | -3.3% | +2.3 pp | Jun 2026 |
| GRAIL, Inc. GRAL | -4.9% | +0.3 pp | Mar 2026 |
| Natera, Inc. NTRA | -5.5% | +0.8 pp | Mar 2026 |
| Twist Bioscience Corporation TWST | -8.5% | −1.3 pp | Mar 2026 |
| Guardant Health, Inc. GH | -9.7% | −1.2 pp | Jun 2026 |
| Personalis, Inc. PSNL | -12% | −3.4 pp | Mar 2026 |
| GeneDx Holdings Corp. WGS | -14% | −13.1 pp | Mar 2026 |
| CareDx, Inc. CDNA | -29% | −25.5 pp | Jun 2026 |
Full 20-quarter history · every available company
ROCE · reported quarter history
Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Agilent Technologies, Inc. · A
—
4.6%
4.5%
4.2%
4.7%
5.3%
4.8%
4.3%
1.5%
4.6%
4.2%
4.0%
3.8%
4.3%
3.9%
3.2%
3.8%
4.4%
3.4%
3.8%
Danaher Corporation · DHR
—
1.8%
—
3.0%
3.0%
2.6%
2.0%
1.5%
1.6%
1.8%
1.7%
1.6%
1.3%
1.9%
1.7%
1.0%
1.6%
2.0%
1.8%
1.4%
Guardant Health, Inc. · GH
-6.5%
-4.7%
-5.9%
-6.7%
-7.9%
-8.5%
-8.4%
-7.2%
-7.3%
-13%
-7.1%
-6.6%
-8.1%
-8.9%
-8.5%
-8.5%
-8.3%
-8.1%
-8.9%
-9.7%
IDEXX Laboratories, Inc. · IDXX
14%
12%
15%
11%
15%
14%
17%
17%
15%
13%
14%
12%
14%
12%
14%
17%
16%
14%
17%
—
Illumina, Inc. · ILMN
—
-5.3%
0.4%
1.7%
-5.7%
-32%
-1.1%
-0.5%
-0.8%
-8.8%
-1.2%
-25%
11%
2.6%
2.5%
5.0%
4.9%
4.1%
4.3%
5.1%
IQVIA Holdings Inc. · IQV
1.6%
2.3%
2.5%
2.4%
2.5%
1.9%
2.4%
2.7%
2.5%
2.5%
2.6%
2.6%
2.8%
3.1%
2.5%
2.5%
2.7%
3.0%
2.5%
2.4%
Labcorp Holdings Inc. · LH
4.6%
4.2%
3.9%
2.4%
2.1%
0.2%
1.9%
1.6%
1.6%
-0.8%
2.1%
2.1%
1.7%
1.5%
2.3%
2.8%
2.6%
1.7%
2.4%
2.8%
Mettler-Toledo International Inc. · MTD
12%
14%
10%
12%
13%
15%
11%
12%
13%
11%
11%
12%
13%
16%
10%
13%
13%
15%
9.8%
13%
Natera, Inc. · NTRA
-16%
-16%
-17%
-20%
-13%
-14%
-14%
-13%
-12%
-7.6%
-6.8%
-4.0%
-3.2%
-5.3%
-6.3%
-8.6%
-7.3%
-1.4%
-5.5%
—
Quest Diagnostics Incorporated · DGX
5.5%
4.4%
4.3%
3.4%
3.3%
1.2%
2.6%
3.0%
2.9%
2.3%
2.6%
3.0%
2.6%
2.8%
2.7%
3.4%
2.8%
2.8%
2.8%
3.2%
Thermo Fisher Scientific Inc. · TMO
—
3.7%
—
4.0%
2.9%
2.4%
—
2.0%
2.0%
2.2%
2.1%
2.2%
2.2%
2.4%
2.0%
2.1%
2.2%
2.5%
2.0%
2.2%
Waters Corporation · WAT
—
8.7%
—
8.2%
8.5%
8.0%
—
7.2%
6.6%
8.3%
4.3%
5.1%
5.7%
7.7%
4.2%
5.1%
5.3%
7.1%
—
-0.4%
ROCE change · reported quarter history
Showing the 12 largest of 30 companies with a series here. The remaining 18 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Agilent Technologies, Inc. · A
—
—
—
—
—
+0.7 pp
+0.3 pp
+0.1 pp
−3.2 pp
−0.7 pp
−0.6 pp
−0.3 pp
+2.3 pp
−0.3 pp
−0.3 pp
−0.8 pp
0.0 pp
+0.1 pp
−0.5 pp
+0.6 pp
Danaher Corporation · DHR
—
—
—
—
—
+0.8 pp
—
−1.5 pp
−1.4 pp
−0.8 pp
−0.3 pp
+0.1 pp
−0.3 pp
+0.1 pp
0.0 pp
−0.6 pp
+0.3 pp
+0.1 pp
+0.1 pp
+0.4 pp
Guardant Health, Inc. · GH
—
—
—
—
−1.4 pp
−3.8 pp
−2.5 pp
−0.5 pp
+0.6 pp
−4.7 pp
+1.3 pp
+0.6 pp
−0.8 pp
+4.3 pp
−1.4 pp
−1.9 pp
−0.2 pp
+0.8 pp
−0.4 pp
−1.2 pp
IDEXX Laboratories, Inc. · IDXX
—
—
—
—
+1.5 pp
+2.4 pp
+1.8 pp
+6.1 pp
+0.1 pp
−1.4 pp
−2.3 pp
−5.0 pp
−1.8 pp
−1.3 pp
−0.3 pp
+4.6 pp
+2.3 pp
+2.8 pp
+3.3 pp
—
Illumina, Inc. · ILMN
—
—
—
—
—
−26.9 pp
−1.5 pp
−2.2 pp
+4.9 pp
+23.4 pp
−0.1 pp
−24.0 pp
+11.6 pp
+11.4 pp
+3.7 pp
+29.5 pp
−5.9 pp
+1.5 pp
+1.8 pp
+0.1 pp
IQVIA Holdings Inc. · IQV
—
—
—
—
+0.9 pp
−0.4 pp
−0.1 pp
+0.3 pp
0.0 pp
+0.6 pp
+0.2 pp
−0.1 pp
+0.3 pp
+0.6 pp
−0.1 pp
−0.1 pp
−0.1 pp
−0.1 pp
0.0 pp
−0.1 pp
Labcorp Holdings Inc. · LH
—
—
—
—
−2.5 pp
−4.0 pp
−2.0 pp
−0.8 pp
−0.5 pp
−1.0 pp
+0.2 pp
+0.5 pp
+0.1 pp
+2.3 pp
+0.2 pp
+0.7 pp
+0.9 pp
+0.2 pp
+0.1 pp
0.0 pp
Mettler-Toledo International Inc. · MTD
—
—
—
—
+1.1 pp
+0.6 pp
+0.4 pp
+0.1 pp
−0.9 pp
−3.9 pp
0.0 pp
−0.2 pp
+0.3 pp
+4.5 pp
−0.2 pp
+0.4 pp
+0.1 pp
−0.8 pp
−0.5 pp
+0.4 pp
Natera, Inc. · NTRA
—
—
—
—
+3.1 pp
+2.5 pp
+2.5 pp
+6.9 pp
+1.1 pp
+5.9 pp
+7.4 pp
+8.6 pp
+8.5 pp
+2.3 pp
+0.5 pp
−4.6 pp
−4.1 pp
+3.9 pp
+0.8 pp
—
Quest Diagnostics Incorporated · DGX
—
—
—
—
−2.2 pp
−3.2 pp
−1.7 pp
−0.4 pp
−0.4 pp
+1.1 pp
0.0 pp
0.0 pp
−0.3 pp
+0.5 pp
+0.1 pp
+0.4 pp
+0.2 pp
0.0 pp
+0.1 pp
−0.2 pp
Thermo Fisher Scientific Inc. · TMO
—
—
—
—
—
−1.3 pp
—
−2.0 pp
−0.9 pp
−0.2 pp
—
+0.2 pp
+0.2 pp
+0.2 pp
−0.1 pp
−0.1 pp
0.0 pp
+0.1 pp
0.0 pp
+0.1 pp
Waters Corporation · WAT
—
—
—
—
—
−0.7 pp
—
−1.0 pp
−1.9 pp
+0.3 pp
—
−2.1 pp
−0.9 pp
−0.6 pp
−0.1 pp
0.0 pp
−0.4 pp
−0.6 pp
—
−5.5 pp
09 · compare level, then change
Valuation Against Growth & Quality
Agilent Technologies, Inc. has the lowest PEG among the 30 Diagnostics & Research companies compared here, at 1.01×. IDEXX Laboratories, Inc. is next at 1.62×. CareDx, Inc. has the lowest P/E at 13.8×, so level and change sit with different companies. 2 of 30 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Agilent Technologies, Inc. has the lowest comparable PEG at 1.01×, 37.7% below IDEXX Laboratories, Inc.. Only 2 of 30 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.
LeaderAgilent Technologies, Inc. · 1.01×
Gap37.7% versus #2 · IDEXX Laboratories, Inc.
Persistence0/8 recent comparable periods
Coverage2/30 companies · 67 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
P/Elowest P/E
Valuation · company comparison
2/30 level · 24/30 change
All-company data · latest reported quarter
| Company | PEG | P/E | Reported |
|---|---|---|---|
| Mettler-Toledo International Inc. MTD | 4.7 | 28.8 | Jun 2026 |
| Waters Corporation WAT | 4.3 | 38.7 | Jun 2026 |
| Thermo Fisher Scientific Inc. TMO | 3.9 | 27.6 | Jun 2026 |
| IQVIA Holdings Inc. IQV | 2.1 | 24.0 | Jun 2026 |
| IDEXX Laboratories, Inc. IDXX | 1.6 | 41.4 | Mar 2026 |
| Revvity, Inc. RVTY | 1.5 | 42.6 | Jun 2026 |
| Quest Diagnostics Incorporated DGX | 1.5 | 22.5 | Jun 2026 |
| Medpace Holdings, Inc. MEDP | 1.4 | 31.0 | Jun 2026 |
| Agilent Technologies, Inc. A | 1.0 | 23.2 | Jun 2026 |
| Labcorp Holdings Inc. LH | 0.8 | 23.2 | Jun 2026 |
| ICON Public Limited Company ICLR | 0.5 | 310.2 | Jun 2026 |
| Danaher Corporation DHR | — | 34.9 | Jun 2026 |
| Illumina, Inc. ILMN | — | 32.9 | Jun 2026 |
| Charles River Laboratories International, Inc. CRL | — | 427.3 | Mar 2026 |
| Qiagen N.V. QGEN | — | 20.9 | Mar 2026 |
| BillionToOne, Inc. BLLN | — | 60.9 | Mar 2026 |
| RadNet, Inc. RDNT | — | 1,746.0 | Mar 2026 |
| Sotera Health Company SHC | — | 35.0 | Mar 2026 |
| Veracyte, Inc. VCYT | — | 41.7 | Jun 2026 |
| CareDx, Inc. CDNA | — | 13.8 | Jun 2026 |
| GeneDx Holdings Corp. WGS | — | 2,693.5 | Mar 2026 |
| NeoGenomics, Inc. NEO | — | 134.0 | Jun 2026 |
| OPKO Health, Inc. OPK | — | 33.2 | Jun 2026 |
| Castle Biosciences, Inc. CSTL | — | 43.0 | Jun 2026 |
Full 20-quarter history · every available company
PEG · reported quarter history
Agilent Technologies, Inc. · A
—
—
—
—
—
—
—
3.2
—
—
—
—
1.1
—
—
—
—
—
—
1.0
ICON Public Limited Company · ICLR
—
—
—
—
—
—
—
—
3.9
3.0
1.6
1.2
0.9
0.6
0.8
0.5
—
—
—
—
IDEXX Laboratories, Inc. · IDXX
—
—
—
—
—
—
—
2.5
1.8
2.2
2.2
6.7
8.4
6.5
—
2.4
2.4
2.3
1.6
—
IQVIA Holdings Inc. · IQV
—
—
—
—
—
—
—
—
—
1.2
1.1
0.8
1.1
—
—
—
—
—
2.1
—
Labcorp Holdings Inc. · LH
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
1.3
0.8
—
Medpace Holdings, Inc. · MEDP
—
—
—
—
—
—
0.5
0.6
0.9
1.6
1.7
1.4
0.9
0.6
0.7
0.9
1.4
1.7
1.4
—
Mettler-Toledo International Inc. · MTD
—
—
—
—
—
—
2.5
2.7
3.8
—
—
—
—
2.3
2.4
3.4
3.8
—
4.7
—
Quest Diagnostics Incorporated · DGX
—
—
—
—
—
—
—
—
—
—
1.9
2.4
1.8
—
3.3
1.7
1.5
1.4
1.5
—
Revvity, Inc. · RVTY
—
—
—
—
—
—
—
—
—
—
—
—
—
1.2
—
—
1.5
—
—
—
Thermo Fisher Scientific Inc. · TMO
—
—
—
—
—
—
—
—
—
—
—
—
—
—
1.7
1.7
3.1
4.5
3.9
—
Waters Corporation · WAT
—
—
—
—
—
—
—
—
—
—
—
—
—
—
4.7
4.3
—
—
—
—
P/E · reported quarter history
Showing the 12 largest of 24 companies with a series here. The remaining 12 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Agilent Technologies, Inc. · A
—
40.0
35.4
28.7
30.6
33.1
34.3
29.8
31.9
24.7
31.0
32.4
29.3
29.4
34.8
26.6
27.0
32.0
29.6
23.2
Danaher Corporation · DHR
—
34.5
—
30.4
26.9
27.8
24.9
26.7
29.8
36.3
43.8
44.0
52.1
43.4
40.0
42.3
38.1
45.3
35.1
34.9
IDEXX Laboratories, Inc. · IDXX
71.2
76.6
64.1
45.3
41.4
50.8
60.2
53.3
44.6
55.2
52.3
48.2
48.7
38.8
38.8
44.7
50.7
51.7
41.4
—
Illumina, Inc. · ILMN
—
63.0
73.4
76.9
—
—
—
—
—
—
—
—
—
—
—
12.0
20.6
24.8
21.4
32.9
IQVIA Holdings Inc. · IQV
60.8
57.0
41.7
36.2
29.5
35.8
35.8
38.7
33.1
31.7
34.6
27.5
31.1
26.2
24.0
22.8
26.1
28.8
21.1
24.0
Labcorp Holdings Inc. · LH
8.6
11.1
10.4
9.6
9.4
14.5
17.9
22.4
26.9
47.7
44.0
38.5
43.2
25.9
26.9
29.0
28.2
24.0
23.6
23.2
Medpace Holdings, Inc. · MEDP
39.1
45.3
30.5
26.0
24.1
29.2
23.8
28.7
28.4
34.5
41.2
38.7
29.2
26.3
23.3
23.3
36.0
36.8
30.2
31.0
Mettler-Toledo International Inc. · MTD
43.2
51.8
40.3
32.4
29.7
37.6
38.9
33.0
28.3
33.8
37.3
38.5
40.4
30.2
29.5
29.8
30.6
33.2
29.6
28.8
Quest Diagnostics Incorporated · DGX
8.7
11.1
9.1
11.1
12.1
19.6
20.9
20.5
18.3
18.4
17.9
18.5
20.9
19.6
21.4
21.5
22.4
19.8
21.7
22.5
Revvity, Inc. · RVTY
—
34.6
26.4
55.8
42.4
35.4
31.2
45.3
59.7
72.8
82.0
83.2
64.7
50.9
45.9
42.4
43.3
46.7
—
42.6
Thermo Fisher Scientific Inc. · TMO
—
26.6
—
30.9
29.2
28.5
—
37.6
35.7
34.4
37.3
34.3
38.5
31.5
29.3
23.6
26.8
32.7
26.0
27.6
Waters Corporation · WAT
—
31.9
—
27.0
29.4
23.5
—
26.9
23.5
30.4
33.8
28.9
34.1
34.6
32.9
31.8
26.8
35.3
—
38.7
10 · before the conclusion, check the blind spots
What can make this comparison misleading?
This Diagnostics & Research comparison names 5 specific ways its own evidence can mislead, all listed below. All 30 companies here report on comparable dates, so no rank carries a stale marker. 1 of the 5 ranked sections has fewer than three usable current readings. A high growth rate can still be a low-base artefact.
Keep these limits visible
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- Thin comparisons: Valuation have fewer than three usable current readings.
11 · evidence and freshness
How was this comparison built?
This comparison is built from the reported filings of 30 Diagnostics & Research companies, normalized to a common $ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-08-04. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.
FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-08-04 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
12 · questions investors ask, short speakable answers
Diagnostics & Research company comparison FAQs
These 22 answers restate the Diagnostics & Research comparison above in question form. Every one is computed from the same 30 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-08-04. Nothing here is estimated, and none of it is a recommendation.
Is the Diagnostics & Research sector outperforming S&P 500?
Diagnostics & Research has outperformed S&P 500 by 38.7% over 52 weeks and 33.7% over 13 weeks. 17 of 29 covered companies beat the S&P 500 on Mansfield relative strength, while 8 of 29 beat the sector itself.
Which Diagnostics & Research company is largest by revenue?
Agilent Technologies, Inc. leads with revenue of $7,232 million, based on 12 of 30 comparable companies through Jun 2026.
Which Diagnostics & Research company is growing fastest?
BillionToOne, Inc. has the fastest current revenue growth at 99.4%, across 12 of 30 comparable companies.
Which Diagnostics & Research company has the strongest 4-Factor Sector Score?
Medpace Holdings, Inc. ranks first at 60.6/100 with 57.8% evidence confidence. The score prioritizes research; it is not a buy recommendation.
Which Diagnostics & Research company has the lowest comparable PEG?
Agilent Technologies, Inc. has the lowest comparable PEG at 1.01, among 2 of 30 companies whose earnings and growth are steady enough for the ratio to mean anything.
How much history does this Diagnostics & Research comparison include?
The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Which Diagnostics & Research company is the biggest?
Agilent Technologies, Inc. is the largest, with trailing-twelve-month revenue of $7,232 million, ahead of IDEXX Laboratories, Inc. at $4,446 million. That covers 12 of 30 companies with comparable reporting through Jun 2026.
Which Diagnostics & Research company has the best profit margins?
IDEXX Laboratories, Inc. has the highest operating margin at 31.8%, from 30 of 30 comparable companies. GRAIL, Inc. shows the biggest recent improvement, at +149.6 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Diagnostics & Research company makes the most profit?
Agilent Technologies, Inc. earns the most, at $1,414 million of trailing-twelve-month net profit, from 12 of 30 comparable companies. Qiagen N.V. has the fastest profit growth at 100%, though growth off a small or recovering profit base overstates how much has actually changed.
Which Diagnostics & Research company earns the highest return on capital?
Medpace Holdings, Inc. leads on return on capital employed at 30.2%, across 30 of 30 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Which Diagnostics & Research stock is the cheapest?
On PEG — where a LOWER number is cheaper — Agilent Technologies, Inc. screens cheapest at 1.01×. Only 2 of 30 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.
Is the Diagnostics & Research sector beating the market?
Diagnostics & Research has outperformed S&P 500 by 38.7% over the last 52 weeks and 33.7% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 17 of 29 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.
Which Diagnostics & Research stock has the strongest price momentum?
CareDx, Inc. has the strongest relative strength against S&P 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Diagnostics & Research company scores highest for research priority?
Medpace Holdings, Inc. scores 60.6 out of 100 with 57.8% evidence confidence, from 21.1 points on growth and earnings, 21.3 on capital efficiency, 10.5 on valuation and 7.7 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Diagnostics & Research companies does this comparison cover, and over what period?
It compares 30 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Diagnostics & Research sector?
The 30 Diagnostics & Research companies on this page carry $784,008 million of combined market value. Thermo Fisher Scientific Inc. is the largest at $208,815 million, about 27% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-04.
What is the Diagnostics & Research sector's P/E ratio?
The median price-to-earnings ratio across the 30 Diagnostics & Research companies on this page is 35×, measured on the 24 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-08-04.
How is the Diagnostics & Research sector performing?
17 of the 29 covered Diagnostics & Research companies are beating S&P 500 on Mansfield relative strength. The sector itself is 38.7% ahead of S&P 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-04.
How many Diagnostics & Research stocks are listed in the US?
This comparison covers 30 listed Diagnostics & Research companies in the US, each above the size floor the site applies. The full ranked list is on this page, with reported fundamentals through Jun 2026. Membership is the full industry list — nothing is dropped for having thin data.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.